参考文献
［1] PONIKOWSKI P，VOORS A A，ANKER S D，et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure：The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC）Developed with the special contribution of the Heart Failure Association（HFA）of the ESC［J］. Eur Heart J，2016，37（27）：2129-2200.
［2] PIEK A，DE BOER R A，SILLJE H H. The fibrosis-cell death axis in heart failure［J］. Heart Fail Rev，2016，21（2）：199-211.
［3] BERNARDO B C，WEEKS K L，PRETORIUS L，et al. Molecular distinction between physiological and pathological cardiac hypertrophy：experimental findings and therapeutic strategies［J］. Pharmacol Ther，2010，128（1）：191-227.
［4] PIEK A，DU W，DE BOER R A，et al. Novel heart failure biomarkers：why do we fail to exploit their potential？［J］. Crit Rev Clin Lab Sci，2018，55（4）：246-263.
［5] MAILLET M，VAN BERLO J H，MOLKENTIN J D. Molecular basis of physiological heart growth：fundamental concepts and new players［J］. Nat Rev Mol Cell Biol，2013，14（1）：38-48.
［6] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints：preferred definitions and conceptual framework［J］. Clin Pharmacol Ther，2001，69（3）：89-95.
［7] MORROW D A，DE LEMOS J A. Benchmarks for the assessment of novel cardiovascular biomarkers［J］. Circulation，2007，115（8）：949-952.
［8] SCHRIER R W，ABRAHAM W T. Hormones and hemodynamics in heart failure［J］. N Engl J Med，1999，341（8）：577-585.
［9] COHN J N，LEVINE T B，OLIVARI M T，et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure［J］. N Engl J Med，1984，311（13）：819-823.
［10] SPINALE F G，ZILE M R. Integrating the myocardial matrix into heart failure recognition and management［J］. Circ Res，2013，113（6）：725-738.
［11] SENTHONG V，KIRSOP J L，TANG W H. Clinical Phenotyping of Heart Failure with Biomarkers：Current and Future Perspectives［J］. Curr Heart Fail Rep，2017，14（2）：106-116.
［12] RICHARDS A M. N-Terminal B-type Natriuretic Peptide in Heart Failure［J］. Heart Fail Clin，2018，14（1）：27-39.
［13] MAISEL A S，DURAN J M，WETTERSTEN N. Natriuretic Peptides in Heart Failure：Atrial and B-type Natriuretic Peptides［J］. Heart Fail Clin，2018，14（1）：13-25.
［14] TIJSEN A J，PINTO Y M，CREEMERS E E. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases［J］.Am J Physiol Heart Circ Physiol，2012，303（9）：H1085-H1095.
［15] DE LEMOS J A，MCGUIRE D K，DRAZNER M H. B-type natriuretic peptide in cardiovascular disease［J］. Lancet，2003，362（9380）：316-322.
［16] VELAGALETI R S，GONA P，LARSON M G，et al. Multimarker approach for the prediction of heart failure incidence in the community［J］. Circulation，2010，122（17）：1700-1706.
［17] GLICK D，DEFILIPPI C R，CHRISTENSON R，et al. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk［J］. JACC Heart Fail，2013，1（4）：353-360.
［18] DEFILIPPI C R，DE LEMOS J A，TKACZUK A T，et al. Physical activity，change in biomarkers of myocardial stress and injury，and subsequent heart failure risk in older adults［J］. J Am Coll Cardiol，2012，60（24）：2539-2547.
［19] DEFILIPPI C R，DE LEMOS J A，CHRISTENSON R H，et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults［J］. JAMA，2010，304（22）：2494-2502.
［20] WALLACE T W，ABDULLAH S M，DRAZNER M H，et al. Prevalence and determinants of troponin T elevation in the general population［J］. Circulation，2006，113（16）：1958-1965.
［21] DANIELS L B，LAUGHLIN G A，CLOPTON P，et al. Minimally elevated cardiac troponin T and elevated N-terminal pro-Btype natriuretic peptide predict mortality in older adults：results from the Rancho Bernardo Study［J］. J Am Coll Cardiol，2008，52（6）：450-459.
［22] GOTTDIENER J S，ARNOLD A M，AURIGEMMA G P，et al. Predictors of congestive heart failure in the elderly：the Cardiovascular Health Study［J］. J Am Coll Cardiol，2000，35（6）：1628-1637.
［23] LAM C S，LYASS A，KRAIGHER-KRAINER E，et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community［J］. Circulation，2011，124（1）：24-30.
［24] DADU R T，DODGE R，NAMBI V，et al. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study ［J］.Circ Heart Fail，2013，6（5）：936-943.
［25] MCMURRAY J J，ADAMOPOULOS S，ANKER S D，et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012：The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association（HFA）of the ESC［J］. Eur Heart J，2012，33（14）：1787-1847.
［26] DOUST J A，PIETRZAK E，DOBSON A，et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure：systematic review［J］. BMJ，2005，330（7492）：625.
［27] LATINI R，MASSON S，ANAND I S，et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure［J］. Circulation，2007，116（11）：1242-1249.
［28] ANAND I S，RECTOR T S，KUSKOWSKI M，et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial［J］.Circ Heart Fail，2014，7（3）：418-426.
［29] HARRISON A，MORRISON L K，KRISHNASWAMY P，et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea［J］. Ann Emerg Med，2002，39（2）：131-138.
［30] MAISEL A，MUELLER C，ADAMS K Jr，et al. State of the art：using natriuretic peptide levels in clinical practice［J］. Eur J Heart Fail，2008，10（9）：824-839.
［31] JANUZZI J L Jr，SAKHUJA R，O'DONOGHUE M，et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department［J］. Arch Intern Med，2006，166（3）：315-320.
［32] JANUZZI J L Jr，PEACOCK W F，MAISEL A S，et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea：results from the PRIDE（Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department）study［J］. J Am Coll Cardiol，2007，50（7）：607-613.
［33] SHAH R V，CHEN-TOURNOUX A A，PICARD M H，et al. Galectin-3，cardiac structure and function，and long-term mortality in patients with acutely decompensated heart failure［J］. Eur J Heart Fail，2010，12（8）：826-832.
［34] MEIJERS W C，JANUZZI J L，DEFILIPPI C，et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure：a pooled analysis of 3 clinical trials［J］. Am Heart J，2014，167（6）：853-860，e854.
［35] CLELAND J G，TAYLOR J，TENDERA M. Prognosis in heart failure with a normal ejection fraction［J］. N Engl J Med，2007，357（8）：829-830.
［36] ANAND I S，RECTOR T S，CLELAND J G，et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction：findings from the I-PRESERVE trial［J］. Circ Heart Fail，2011，4（5）：569-577.
［37] JHUND P S，ANAND I S，KOMAJDA M，et al. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction：an analysis of the I-Preserve study［J］. Eur J Heart Fail，2015，17（8）：809-817.
［38] ZILE M R，BAICU C F，IKONOMIDIS J S，et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction：contributions of collagen and titin［J］. Circulation，2015，131（14）：1247-1259.